Towards Personalized Medicine for Obstructive Sleep Apnea

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: closed (31 May 2024) | Viewed by 1644

Special Issue Editors


E-Mail Website
Guest Editor
Translational Neurosciences, Universitair Ziekenhuis Antwerpen, Edegem, Belgium
Interests: obstructive sleep apnea; mandibular advancement device; positional therapy; personalized treatment

E-Mail Website
Guest Editor
Translational Neurosciences, Universitair Ziekenhuis Antwerpen, Edegem, Belgium
Interests: obstructive sleep apnea; pathophysiology; personalized treatment

E-Mail Website
Guest Editor
Department of Translational neurosciences, Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk, Belgium
Interests: obstructive sleep apnea; upper airway surgery; drug-induced sleep endoscopy; personalized treatment

Special Issue Information

Dear Colleagues,

Obstructive sleep apnea (OSA) is a highly prevalent disease, associated with multiple comorbidities. While OSA is defined as the repetitive closure or narrowing of the upper airway, the exact mechanisms of this disorder in each individual patient remain unknown. However, it has been shown that underlying differences in OSA mechanisms can affect treatment outcomes. Indeed, endotypes such as the site of upper airway collapse, pathophysiology or health parameters such as BMI and comorbidities were found to be associated with one or more OSA treatment outcomes or adherence.

This Life Special Issue, “Towards Precision Medicine for Obstructive Sleep Apnea”, will collect manuscripts on original data and reviews covering this topic. The scope covers novel findings in predictors for OSA treatment, based on endotyping, cardiovascular parameters, biomarkers, etc. but also welcomes fundamental research on OSA mechanisms and reviews. As such, we aim to provide a broad overview of fundamental OSA mechanisms and how these could be used as the next steps towards personalized medicine.

Dr. Marijke Dieltjens
Dr. Sara Op De Beeck
Dr. Olivier M. Vanderveken
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • obstructive sleep apnea
  • personalized treatment
  • drug-induced sleep endoscopy
  • pathophysiology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1269 KiB  
Article
Hypoglossal Nerve Stimulation Therapy in a Belgian Cohort of Obstructive Sleep Apnea Patients
by Dorine Van Loo, Marijke Dieltjens, Sanne Engelen, Johan Verbraecken and Olivier M. Vanderveken
Life 2024, 14(7), 788; https://doi.org/10.3390/life14070788 - 21 Jun 2024
Viewed by 1239
Abstract
Hypoglossal nerve stimulation (HGNS) has emerged as a widespread and innovative treatment option for selected moderate-to-severe obstructive sleep apnea (OSA) patients who cannot be treated effectively with traditional treatment modalities. In this observational cohort study, the objective and subjective outcomes of Belgian OSA [...] Read more.
Hypoglossal nerve stimulation (HGNS) has emerged as a widespread and innovative treatment option for selected moderate-to-severe obstructive sleep apnea (OSA) patients who cannot be treated effectively with traditional treatment modalities. In this observational cohort study, the objective and subjective outcomes of Belgian OSA patients treated with HGNS therapy were analyzed at 6 and 12 months post-implantation. Thirty-nine patients implanted with a respiration-synchronized HGNS device at the Antwerp University Hospital w ere included in this study. Patients underwent baseline in-laboratory polysomnography and a follow-up sleep study 6 and 12 months post-implantation. Questionnaires on patient experience and daytime sleepiness were filled out and data on objective therapy usage were collected. All 39 patients completed the 6-month follow-up and 21 patients (54%) completed the 12-month follow-up. Median AHI decreased from 33.8 [26.1;45.0] to 10.2 [4.8;16.4] at the 6-month follow-up, and to 9.6 [4.1;16.4] at the 12-month follow-up (p < 0.001). The surgical success rate, according to the Sher20 criteria, was 80% and 76% at the 6- and 12-month follow-ups, respectively. Median ESS improved from 12.0 [7.0;18.0] at baseline to 6.0 [2.5;11.0] at 6 months (p < 0.001) and to 6.5 [2.8;11.5] at 12 months (p = 0.012). Objective therapy usage was 7.4 [6.6;8.0] and 7.0 [5.9:8.2] h/night at the 6- and 12-month follow-ups, respectively. A high overall clinical effectiveness of HGNS therapy, as shown by a mean disease alleviation of 58%, was demonstrated at 12 months post-implantation. Overall, HGNS therapy using respiration-synchronized neurostimulation of the XII cranial nerve resulted in a significant improvement in both objective and subjective OSA outcomes, with a high level of patient satisfaction and high treatment adherence. Full article
(This article belongs to the Special Issue Towards Personalized Medicine for Obstructive Sleep Apnea)
Show Figures

Figure 1

Back to TopTop